Metabolomics and NMR applied to in vivo studies
We are pleased to present examples of application of NMR metabolomics to drug candidate in vivo testing.
Together with our partners, we assist our clients with their research to obtain the most relevant data in the most cost-effective manner. Our collaboration with Giotto Biotech allows us to offer state of the art NMR metabolomic analysis in all in vivo studies.
We provide a metabolomic analysis of in vivo study samples that substantially increase the quantity and quality of data from a single study in a time and cost efficient manner. Metabolomic data can improve toxicology studies and the drug development process.
The advantages of NMR metabolomics are high reproducibility, a wide range over which the results are quantitative, is very well suited for compound identification, can be used for tracing metabolic pathways, is non-destructive and has a proven track record of translating in vitro results to in vivo applications.
To improve the efficacy of the drug development process, it is necessary to obtain maximum information from each animal study. There are various ways to achieve this goal, such as metabolomic profiling of biological fluids and various organ tissues, disease metabolomics finger-printing and identification of metabolomics cancer markers. Additionally, a metabolomic profile allows an analysis of the treatment effect with a new drug candidate at the molecular level both in the healthy and tumor tissue.
Toxicology studies can greatly benefit from metabolomic data. As there is a correlation between extracellular metabolites and the intracellular situation, analysis of metabolomic profiles of either body fluid samples or organs can provide information on organ specific toxicity and an insight into a drug‘s mode of action. An added benefit is that body fluid sampling is non-invasive, therefore a large quantity of data can be obtained during the course of a toxicology study and not only at the study end-point.
Metabolomics are also very useful in the field of drug development with the potential to identify and validate novel therapeutic targets, creating alternative screening protocols, helping in the selection of cancer metabolite biomarkers, disease fingerprinting and identifying metabolite signatures for the drug efficacy mechanism of action.
To download the application examples, please click here.